These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15936869)

  • 1. Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow.
    Chapple CR; Abrams P
    Eur Urol; 2005 Jul; 48(1):102-9. PubMed ID: 15936869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder.
    Zinner N; Tuttle J; Marks L
    World J Urol; 2005 Sep; 23(4):248-52. PubMed ID: 16096831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers.
    Kay GG; Wesnes KA
    BJU Int; 2005 Nov; 96(7):1055-62. PubMed ID: 16225528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
    Haab F; Stewart L; Dwyer P
    Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
    Foote J; Glavind K; Kralidis G; Wyndaele JJ
    Eur Urol; 2005 Sep; 48(3):471-7. PubMed ID: 15990219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
    Abrams P; Cardozo L; Chapple C; Serdarevic D; Hargreaves K; Khullar V;
    Int J Urol; 2006 Jun; 13(6):692-8. PubMed ID: 16834644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
    Chapple C; Steers W; Norton P; Millard R; Kralidis G; Glavind K; Abrams P
    BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist.
    Steers W; Corcos J; Foote J; Kralidis G
    BJU Int; 2005 Mar; 95(4):580-6. PubMed ID: 15705084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M;
    Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study.
    Haab F; Corcos J; Siami P; Glavind K; Dwyer P; Steel M; Kawakami F; Lheritier K; Steers WD
    BJU Int; 2006 Nov; 98(5):1025-32. PubMed ID: 16879437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of health-related quality of life outcomes with darifenacin.
    Abrams P; Kelleher C; Huels J; Quebe-Fehling E; Omar MA; Steel M
    BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects.
    Kay G; Crook T; Rekeda L; Lima R; Ebinger U; Arguinzoniz M; Steel M
    Eur Urol; 2006 Aug; 50(2):317-26. PubMed ID: 16687205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased warning time with darifenacin: a new concept in the management of urinary urgency.
    Cardozo L; Dixon A
    J Urol; 2005 Apr; 173(4):1214-8. PubMed ID: 15758755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB.
    Zinner N; Susset J; Gittelman M; Arguinzoniz M; Rekeda L; Haab F
    Int J Clin Pract; 2006 Jan; 60(1):119-26. PubMed ID: 16409440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
    Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
    Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of cognitive function of the elderly population: effects of darifenacin.
    Lipton RB; Kolodner K; Wesnes K
    J Urol; 2005 Feb; 173(2):493-8. PubMed ID: 15643227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study.
    Dwyer P; Kelleher C; Young J; Haab F; Lheritier K; Ariely R; Ebinger U
    Neurourol Urodyn; 2008; 27(6):540-7. PubMed ID: 18663723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial.
    Wang AC; Chih SY; Chen MC
    Urology; 2006 Nov; 68(5):999-1004. PubMed ID: 17113893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.
    Chapple C; DuBeau C; Ebinger U; Rekeda L; Viegas A
    Curr Med Res Opin; 2007 Oct; 23(10):2347-58. PubMed ID: 17706004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
    Stöhrer M; Mürtz G; Kramer G; Schnabel F; Arnold EP; Wyndaele JJ;
    Eur Urol; 2007 Jan; 51(1):235-42. PubMed ID: 16698176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.